Testing Data
(ELISA plate was coated with serially diluted Human IgG1 Kappa-UNLB. Immunoglobulin was detected with Mouse Anti-Human IgG1 Hinge-BIOT, Mouse Anti-Human IgG2 Fc-BIOT, Mouse Anti-Human IgG3 Hinge-BIOT, Mouse Anti-Human IgG4 pFc'-BIOT, Mouse Anti-Human IgA1-BIOT, Mouse Anti-Human IgA2-BIOT, Mouse Anti-Human IgD-BIOT, Mouse Anti-Human IgE Fc-BIOT, Mouse Anti-Human IgM-BIOT, Mouse Anti-Human Kappa-BIOT, and Mouse Anti-Human Lambda-BIOT followed by Streptavidin-HRP and quantified.)
Human IgG1 Kappa Antibody | anti-IgG1 Kappa antibody
Human IgG1 Kappa-BIMA
Applications
ELISA
Synonyms
IgG1 Kappa; Human IgG1 Kappa-BIMA; anti-IgG1 Kappa antibody
Host
Human
Isotype
IgG1
Form/Format
Supplied in PBS/NaN3
Concentration
0.5 mg/mL (varies by lot)
Applicable Applications for anti-IgG1 Kappa antibody
ELISA (EIA), FLISA
Source Note
Human myeloma serum
Conjugation
BIMA (Biotin Maleimide)
Preparation and Storage
Store at 2-8 degree C.
Testing Data
(ELISA plate was coated with serially diluted Human IgG1 Kappa-UNLB. Immunoglobulin was detected with Mouse Anti-Human IgG1 Hinge-BIOT, Mouse Anti-Human IgG2 Fc-BIOT, Mouse Anti-Human IgG3 Hinge-BIOT, Mouse Anti-Human IgG4 pFc'-BIOT, Mouse Anti-Human IgA1-BIOT, Mouse Anti-Human IgA2-BIOT, Mouse Anti-Human IgD-BIOT, Mouse Anti-Human IgE Fc-BIOT, Mouse Anti-Human IgM-BIOT, Mouse Anti-Human Kappa-BIOT, and Mouse Anti-Human Lambda-BIOT followed by Streptavidin-HRP and quantified.)
Testing Data
(ELISA plate was coated with serially diluted Human IgG1 Kappa-UNLB. Immunoglobulin was detected with Mouse Anti-Human IgG1 Hinge-BIOT, Mouse Anti-Human IgG2 Fc-BIOT, Mouse Anti-Human IgG3 Hinge-BIOT, Mouse Anti-Human IgG4 pFc'-BIOT, Mouse Anti-Human IgA1-BIOT, Mouse Anti-Human IgA2-BIOT, Mouse Anti-Human IgD-BIOT, Mouse Anti-Human IgE Fc-BIOT, Mouse Anti-Human IgM-BIOT, Mouse Anti-Human Kappa-BIOT, and Mouse Anti-Human Lambda-BIOT followed by Streptavidin-HRP and quantified.)
References
1. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545-52. (ELISA, in vivo control, Surface plasmon resonance)
2. Zhang J, Jacobi AM, Wang T, Berlin R, Volpe BT, Diamond B. Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. J Autoimmun. 2009;33:270-4. (ELISA)
3. Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med. 2013;210:241-56. (IP)
4. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol. 2010;66:869-80. (In vitro control)
5. Li J, Jie H, Lei Y, Gildener-Leapman N, Trivedi S, Green T, et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015;75:508-18. (In vitro control)
6. Li J, Srivastava RM, Ettyreddy A, Ferris RL. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. J Immunother Cancer. 2015;3:54. (In vitro control, Block)
7. Woess C, Tuzlak S, Labi V, Drach M, Bertele D, Schneider P, et al. Combined loss of the BH3-only proteins Bim and Bmf restores B-cell development and function in TACI-Ig transgenic mice. Cell Death Differ. 2015;22:1477-88. (In vivo control)
8. Hotard AL, Lee S, Currier MG, Crowe JE Jr, Sakamoto K, Newcomb DC, et al. Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis. J Virol. 2015;89:512-22. (FC)
9. Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55:1545-54. (FC)
10. Ortiz DF, Lansing JC, Rutitzky L, Kurtagic E, Prod'homme T, Choudhury A, et al. Elucidating the interplay between IgG-Fc valency and FcgammaR activation for the design of immune complex inhibitors. Sci Transl Med. 2016;8:365ra158. (Stim)
11. Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal Chem. 2010;82:5219-26. (Mass spectrometry)
2. Zhang J, Jacobi AM, Wang T, Berlin R, Volpe BT, Diamond B. Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. J Autoimmun. 2009;33:270-4. (ELISA)
3. Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med. 2013;210:241-56. (IP)
4. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol. 2010;66:869-80. (In vitro control)
5. Li J, Jie H, Lei Y, Gildener-Leapman N, Trivedi S, Green T, et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015;75:508-18. (In vitro control)
6. Li J, Srivastava RM, Ettyreddy A, Ferris RL. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. J Immunother Cancer. 2015;3:54. (In vitro control, Block)
7. Woess C, Tuzlak S, Labi V, Drach M, Bertele D, Schneider P, et al. Combined loss of the BH3-only proteins Bim and Bmf restores B-cell development and function in TACI-Ig transgenic mice. Cell Death Differ. 2015;22:1477-88. (In vivo control)
8. Hotard AL, Lee S, Currier MG, Crowe JE Jr, Sakamoto K, Newcomb DC, et al. Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis. J Virol. 2015;89:512-22. (FC)
9. Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55:1545-54. (FC)
10. Ortiz DF, Lansing JC, Rutitzky L, Kurtagic E, Prod'homme T, Choudhury A, et al. Elucidating the interplay between IgG-Fc valency and FcgammaR activation for the design of immune complex inhibitors. Sci Transl Med. 2016;8:365ra158. (Stim)
11. Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal Chem. 2010;82:5219-26. (Mass spectrometry)
Similar Products
Product Notes
The IgG1 Kappa (Catalog #AAA679327) is an Antibody produced from Human and is intended for research purposes only. The product is available for immediate purchase. AAA Biotech's IgG1 Kappa can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), FLISA. Researchers should empirically determine the suitability of the IgG1 Kappa for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "IgG1 Kappa, Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
